title: Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial.
authors.affiliation: J.G. Mudd Cardiac Catheterization Laboratory, St. Louis University Health Sciences Center, 3635 Vista Avenue at Grand, St. Louis, MO, 63110, USA.
authors.initials: FV
authors.lastname: Aguirre
authors.initials: EJ
authors.lastname: Topol
authors.initials: KM
authors.lastname: Anderson
authors.initials: NS
authors.lastname: Kleiman
authors.initials: HF
authors.lastname: Weisman
authors.initials: SE
authors.lastname: FitzPatrick
authors.initials: RM
authors.lastname: Califf